← Back to Search

Electronic Educational Message with Tailored Questions/Prompts for Vaccine Refusal

N/A

Recruiting

Led By Judith A James, MD, PhD

Research Sponsored by University of Oklahoma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to month 2

Awards & highlights

Study Summary

This trial will work to improve vaccine uptake among Oklahoma's underserved populations who have been hit hardest by COVID-19.

Eligible Conditions

Vaccine Refusal
COVID-19
Coronavirus

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to month 2

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to month 2

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to month 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of participants who plan to receive a COVID-19 vaccine post-intervention

Secondary outcome measures

Percentage of participants who self-report COVID-19 vaccine uptake

Trial Design

8Treatment groups

Experimental Treatment

Active Control

Group I: Condition 8Experimental Treatment2 Interventions

Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.

Group II: Condition 7Experimental Treatment1 Intervention

Group III: Condition 6Experimental Treatment2 Interventions

Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.

Group IV: Condition 5Experimental Treatment3 Interventions

Group V: Condition 4Experimental Treatment2 Interventions

Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.

Group VI: Condition 3Experimental Treatment1 Intervention

Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.

Group VII: Condition 2Experimental Treatment1 Intervention

Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.

Group VIII: Condition 1Active Control1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Text Message

2011

Completed Phase 1

~35920

Motivational Interviewing

2020

Completed Phase 3

~8850

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor

455 Previous Clinical Trials

95,610 Total Patients Enrolled

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,950,588 Total Patients Enrolled

2 Trials studying Vaccine Refusal

73 Patients Enrolled for Vaccine Refusal

National Institute of General Medical Sciences (NIGMS)NIH

268 Previous Clinical Trials

246,760 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the scope of this research in terms of participant numbers?

"Affirmative. Data shared on clinicaltrials.gov suggests that this research is actively seeking participants, with 2000 required from a single site since the trial's posting date of March 25th 2022 and last update on August 29th 2022."

Answered by AI

Is this experiment open to aged individuals over the age of seventy-five?

"This trial is open to anyone over 18 and younger than a century."

Answered by AI

Is enrollment for the trial still open?

"Affirmative. The clinicaltrials.gov page shows that this study, which was first posted on March 25th 2022, is currently recruiting participants. A total of 2000 patients need to be admitted from just one medical centre."

Answered by AI

What criteria must a potential participant meet to qualify for this clinical experiment?

"This clinical trial is enrolling 2000 individuals aged 18-100 with vaccine refusal. In addition, participants must meet the following conditions: be of legal age or older; have not received a prior dose of either Pfizer-BioNTech, Moderna, or Janssen vaccines; waited at least 21 days after first Pfizer-BioNTech dose for second shot; and waited 28 days since initial Moderna injection before having another one. Immunocompromised patients can receive third doses either from Pfizer/Moderna at a minimum interval of 28 days apart or two shots from Janssen separated by 2 months. Lastly,"

Answered by AI